Prevalence of Primary Aldosteronism Among Hypertensive Patients With Atrial Arythmia

Last updated: August 21, 2023
Sponsor: Centre Hospitalier de PAU
Overall Status: Completed

Phase

N/A

Condition

Chest Pain

Arrhythmia

Cardiac Disease

Treatment

Primary Hyperaldosteronism diagnostic

Clinical Study ID

NCT04115280
CHPAU2019/01
  • Ages 18-65
  • All Genders

Study Summary

Atrial arrhythmia is the most frequent cardiac arrhythmia. It is a source of significant morbidity.

Hypertension is a major risk factor for atrial arrhythmias. Primary hyperaldosteronism (PA) is a common cause of secondary hypertension, associated with a high prevalence of arrhythmias with a specific, sometimes curative, treatment. The purpose of the study is to show that the prevalence of PA among hypertensive patients under 65 years old with atrial arrhythmia is high, justifying systematic screening.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Hypertensive patients aged of 18 to 65 years with atrial arrhythmia.

Exclusion

Exclusion Criteria:

  • BMI above 30
  • Any situation where the discontinuation of treatments (including betablockers anddiuretics) presents a risk according to the investigator

Study Design

Total Participants: 300
Treatment Group(s): 1
Primary Treatment: Primary Hyperaldosteronism diagnostic
Phase:
Study Start date:
April 16, 2020
Estimated Completion Date:
July 26, 2023

Study Description

Atrial arrhythmia is the most frequent cardiac arrhythmia, affecting one million patients in France. It is a source of significant morbidity, a major deterioration in the quality of life and considerable health expenditure.

Hypertension is a major and modifiable risk factor for atrial arrhythmias. Primary hyperaldosteronism is a common cause of secondary hypertension, associated with a high prevalence of arrhythmias, but also stroke, coronary artery disease, heart and kidney failure. This form has a specific treatment, sometimes curative.

The objective of this study is to show that the prevalence of primary hyperaldosteronism among patients under 65 with atrial arrhythmias is high, justifying systematic screening in this population.

The investigators will consecutively include 65-year-old hypertensive patients hospitalized in the department with atrialarrhythmia. They will benefit from an aldosterone to renin ratio assay under standardized conditions at 3 months.

Patients whose aldosterone (pmol/l) to renin (mUI/l) ratio is greater than 64 will benefit from saline infusion test if necessary and adrenal scan. Patients with a definite diagnosis who would prefer surgical treatment will benefit from adrenal venous catheterization.

Connect with a study center

  • CHU de Bordeaux

    Bordeaux,
    France

    Site Not Available

  • CH de Pau

    PAU,
    France

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.